Publisher
Springer Science and Business Media LLC
Reference22 articles.
1. Wang H, Chen Y, Li F, Delasalle K, Wang J, Alexanian R, Kwak L, Rustveld L, Du XL, Wang M (2012) Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study. Cancer 118:3793–3800
2. Brandefors L, Kimby E, Lundqvist K, Melin B, Lindh J (2016) Familial Waldenstrom’s macroglobulinemia and relation to immune defects, autoimmune diseases, and hematological malignancies—a population-based study from northern Sweden. Acta Oncol 55:91–98
3. Stein HM-HH, Muller-Hermelink HK, Montserrat E, Catovsky D, Campo E, Harris NL, Stein H et al (2008) Chronic lymphocytic leukemia/small lymphocytic lymphoma. In: Swerdlow S, Campo E, Harris NL et al (eds) International Agency for Research on Cancer. WHO classification of tumors of hematopoietic and lymphoid tissue. 4. World Health Organization, Geneva, pp 180–182
4. Gertz MA (2019) Waldenström macroglobulinemia: 2019 update on diagnosis, risk stratification, and management. Am J Hematol 94(2):266–276. https://doi.org/10.1002/ajh.25292
5. Castillo JJ, Olszewski AJ, Kanan S, Meid K, Hunter ZR, Treon SP (2015) Overall survival and competing risks of death in patients with Waldenstrom macroglobulinaemia: an analysis of the surveillance, epidemiology, and end results database. Br J Haematol 169(1):81–89